Investment Analysts’ Recent Ratings Updates for Urogen Pharma (URGN)

Several brokerages have updated their recommendations and price targets on shares of Urogen Pharma (NASDAQ: URGN) in the last few weeks:

• 7/21/2026 – Urogen Pharma had its price target raised by Guggenheim from $32.00 to $42.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Urogen Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Urogen Pharma had its price target raised by Oppenheimer Holdings, Inc. from $40.00 to $50.00. They now have an “outperform” rating on the stock.
• 7/15/2026 – Urogen Pharma had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $44.00 price target on the stock.
• 7/9/2026 – Urogen Pharma had its “buy” rating reaffirmed by UBS Group AG.
• 7/9/2026 – Urogen Pharma had its “buy” rating reaffirmed by HC Wainwright.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider directly owned 119,763 shares of the company’s stock, valued at $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,222 shares of company stock worth $892,661 over the last quarter. 4.80% of the stock is owned by insiders.

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.